A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors (NCT02988960)

🧪 Interventions in This Study

• ABBV-927 (DRUG)
• ABBV-927 (DRUG)
• ABBV-181 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (22 Sites)

• The Angeles Clinic and Researc /ID# 156324 — Los Angeles, California
• The University of Chicago Medical Center /ID# 155264 — Chicago, Illinois
• Massachusetts General Hospital /ID# 155267 — Boston, Massachusetts
• Carolina BioOncology Institute /ID# 155265 — Huntersville, North Carolina
• Tennessee Oncology-Nashville Centennial /ID# 158654 — Nashville, Tennessee
• University of Texas MD Anderson Cancer Center /ID# 155263 — Houston, Texas
• Virginia Cancer Specialists - Fairfax /ID# 155266 — Fairfax, Virginia
• Peninsula Oncology Centre /ID# 164372 — Frankston, Victoria
• Austin Health /ID# 171189 — Heidelberg, Victoria
• University Health Network_Princess Margaret Cancer Centre /ID# 200819 — Toronto, Ontario
• Institut Bergonie /ID# 162665 — Bordeaux, Gironde
• Duplicate_Institut Regional du Cancer /ID# 163609 — Montpellier, Herault
• Centre Leon Berard /ID# 162663 — Lyon, Rhone
• Institut Gustave Roussy /ID# 162666 — Villejuif, Val-de-Marne
• National Cancer Center Hospital East /ID# 216870 — Kashiwa-shi, Chiba
• National Cancer Center Hospital /ID# 217758 — Chuo-ku, Tokyo
• Seoul National University Hospital /ID# 166291 — Seoul, Seoul Teugbyeolsi
• Yonsei University Health System Severance Hospital /ID# 166292 — Seoul,
• Hospital Universitario Puerta de Hierro - Majadahonda /ID# 200129 — Majadahonda, Madrid
• Hospital Universitario Fundacion Jimenez Diaz /ID# 200128 — Madrid,
• Hospital Universitario HM Sanchinarro /ID# 200127 — Madrid,
• Hospital Universitario y Politecnico La Fe /ID# 200975 — Valencia,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumors Cancer

• A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors — Scottsdale, Arizona
• Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors — Boston, Massachusetts
• Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors — Springdale, Arkansas
• A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. — Los Angeles, California
• ORB-021 In Patients With Advanced Solid Tumors — Scottsdale, Arizona

Explore by condition: All Advanced Solid Tumors Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.